Epigenetic Reader Domain
All Product Categories
-
Epigenetic Reader Domain Inhibitors
(341)
View all products
-
Epigenetic Reader Domain Agonists
(2)
View all products
-
Epigenetic Reader Domain Antagonists
(2)
View all products
-
Epigenetic Reader Domain Activators
(3)
View all products
-
Epigenetic Reader Domain Modulators
(2)
View all products
-
Epigenetic Reader Domain Chemicals
(2)
View all products
-
Epigenetic Reader Domain Degraders
(29)
View all products
-
Epigenetic Reader Domain Controls
(12)
View all products
-
Epigenetic Reader Domain Substrate
(1)
View all products
-
Epigenetic Reader Domain Ligands
(5)
View all products
-
Epigenetic Reader Domain Related Products (447)
Related Products (447)
-
MI-538
0 ImagesMI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC50 of 21 nM.
-
KMI169
0 ImagesCat. No.: HY-157486Purity: 98.00%KMI169 is a potent and selective inhibitor targeting lysine methyl-transferase (KMT9) (IC50 = 0.05 μM, Kd = 0.025 μM). KMI169 functions as a bi-substrate inhibitor targeting the cofactor S-5’-adenosyl-L-methionine (SAM) and substrate binding pockets of KMT9. KMI169 can downregulate target genes involved in cell cycle regulation and impair proliferation of tumor cells by inhibiting KMT9. KMI169 is a valuable tool to probe cellular KMT9 functions and can be research for combating diseases including prostate, lung, colon, and invasive bladder cancer.
-
VTP50469 fumarate
0 ImagesSynonyms: SNDX-50469 fumarateVTP50469 fumarate is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 fumarate has potently anti-leukemia activity.
-
PBRM1-BD2-IN-5
0 ImagesPBRM1-BD2-IN-5 is a potent PBRM1 Bromodomain inhibitor with Kd values of 1.5 μM and 3.9 μM for PBRM1-BD2 and PBRM1-BD5, respectively, and an IC50 value of 0.26 μM for PBRM1-BD2. PBRM1-BD2-IN-5 reduces the binding of full-length PBRM1 within the PBAF complex in cell lysates to acetylated histone peptide. PBRM1-BD2-IN-5 can be used to research anticancer.
-
MS31 trihydrochloride
0 ImagesMS31 trihydrochloride is a potent, highly affinity and selective fragment-like methyllysine reader protein spindlin 1 (SPIN1) inhibitor. MS31 trihydrochloride potently inhibits the interactions between SPIN1 and H3K4me3 (IC50=77 nM, AlphaLISA; 243 nM, FP). MS31 trihydrochloride selectively binds Tudor domain II of SPIN1 (Kd=91 nM). MS31 trihydrochloride potently inhibits binding of trimethyllysine-containing peptides to SPIN1, and is not toxic to nontumorigenic cells.
-
DN02
0 ImagesDN02 is a potent, selective BRD8 bromodomain probe. DN02 has exhibits high affinity for the BRD8 (1) (Ki=32 nM), which is 30-fold more affinity than BRD8 (2) (Ki>1000 nM).
-
XX-650-23
0 ImagesXX-650-23 is a potent CREB inhibitor. XX-650-23inhibits CREB function through disruption of CBP-CREB interaction. XX-650-23 can be used for AML research.
-
(R)-JQ-1 carboxylic acid
0 Images(R)-JQ-1 carboxylic acid, is an isomer of JQ-1 carboxylic acid (HY-78695). JQ-1 carboxylic acid, a (+)-JQ-1 (HY-13030) derivative, is a potent BET bromodomain inhibitor. JQ-1 carboxylic acid can be used to synthesize PROTAC, which can target the degradation of BRD4.
-
Molibresib besylate
0 ImagesCat. No.: HY-13032BCAS No.: 1895049-20-3Synonyms: GSK 525762C; I-BET 762 besylateMolibresib besylate (GSK 525762C; I-BET 762 besylate) is an orally active pan-BET inhibitor that targets and binds to BRD2, BRD3, BRD4 and BRDT. By competitively occupying acetylated lysine binding sites, Molibresib besylate disrupts the interaction between BET proteins and chromatin, thereby effectively inhibiting MYC expression and target gene transcription. Molibresib besylate exhibits broad antiproliferative activity, which not only inhibits cancer cell growth and induces growth arrest, but also downregulates mitosis-related genes and upregulates the level of p-ERK1/2. When combined with MEK inhibitors, Molibresib besylate shows a significant synergistic effect, reduces tumor burden in mouse models of leukemia, modulates the immune microenvironment and prolongs survival. Molibresib besylate is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer and various advanced refractory solid tumors.
-
MI-3
0 ImagesSynonyms: Menin-MLL inhibitor 3MI-3 (Menin-MLL inhibitor 3) is a potent and high affinity menin-MLL inhibitor with an IC50 of 648 nM and a Kd of 201 nM.
-
PROTAC BRD4 Degrader-8
0 ImagesPROTAC BRD4 Degrader-8 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC50s of 1.1 nM and 1.4 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-8 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells.
-
ZL0590
0 ImagesZL0590 is a potent, orally active BRD4 BD1-selective inhibitor with an IC50 of 90 nM for human BRD4 BD1. ZL0590 exhibits significant anti-inflammatory activities. ZL0590 can reduce mucosal inflammation in animal models of inflammatory bowel disease and restores tissue architecture. ZL0590 can be used in research on inflammatory diseases such as inflammatory bowel disease.
